STAT+: Pharmalittle: We’re reading about concerns over a rare disease drug, pharma payments to docs, and more
Patient advocates and some experts are expressing growing alarm over the perceived risks of a Neurocrine Biosciences rare disease drug
In the early hours of a typically pleasant day at the Pharmalot campus, the focus turns to a rare disease drug and the concerns surrounding it. The story, reported by STAT, highlights the potential safety issues associated with Neurocrine Biosciences' Vykat XR.
The drug, approved for treating Prader-Willi syndrome, has been linked to the deaths of seven individuals and hospitalizations of nearly 100 others since its approval 18 months ago. Although case reports submitted to regulators cannot definitively prove causality, many Vykat cases involved complex medical issues and multiple medications. Some experts, however, believe the evidence is strong enough to conclude that Vykat is causing unacceptable harm.
Moreover, the story discusses the financial side of the matter. The gifts and payments that doctors receive from drugmakers are thought to contribute to inappropriate prescribing, leading to increased healthcare costs. A Cochrane review of dozens of previous studies supports this claim, suggesting that pharmaceutical industry influence on medical practice may have a negative impact.
However, the story also mentions that conflict-of-interest policies, which restrict or manage interactions between companies and doctors, have improved prescribing practices. As readers, we are encouraged to continue the discussion in STAT+.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
